Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Melanoma 3Lymphoma, Non-Hodgkin 3Recurrence 2Prostatic Neoplasms 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, B-Cell 2Lymphoma 2Neoplasm Metastasis 1Lymphatic Diseases 1Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Burkitt Lymphoma 1Breast Neoplasms 1

Interventions

Cyclophosphamide 5blinatumomab 4Rituximab 3Brentuximab Vedotin 3fludarabine phosphate 2fludarabine 2dacetuzumab 2cobomarsen 2Whole-Body Irradiation 2Vincristine 2Tacrolimus 2Prednisone 2Peripheral Blood Stem Cell Transplantation 2Patient Reported Outcome Measures 2Mycophenolic Acid 2Mesna 2Melphalan 2Ifosfamide 2Everolimus 2Etoposide 2Doxorubicin 2Carboplatin 2Busulfan 2sepantronium 1pomalidomide 1pembrolizumab 1Vorinostat 1DTRMWXHS-12 1Bone Marrow Transplantation 1Bendamustine Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Lymphatic Diseases × sepantronium × Clear all
NCT05263583 2025-01-14

Sepantronium Bromide for the Treatment of High-grade B-cell Lymphoma

Cothera Bioscience, Inc

Phase 2 Active not recruiting
14 enrolled
Lymphoid

Burkitt Lymphoma, Lymphatic Diseases, Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡